Felipe Duran
Known title: Chief Financial OfficerCIK: 0001964267
Felipe Duran's purchase track record
Felipe Duran has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/19/2026 | IBIO | $50K | -19.5% | -40.5% | +15.6% |
| 1/10/2025 | IBIO | $25K | -52.9% | -68.2% | +7.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IBIO | ▲ Buy | Open Market | 24,835 | $50K | 3/19/2026 | View on chart |
| IBIO | ▲ Buy | Open Market | 9,191 | $25K | 1/10/2025 | View on chart |
| IBIO | ▲ Buy | Grant | 37,500 | $0 | 3/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
iBio to Present Data at 2026 EASD Annual Meeting
iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.
iBio to Present Data at 2026 EASD Annual Meeting. iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.